Management of Ventricular Tachycardia

Introduction to Ventricular Tachycardia Management

The American Heart Association and the European Society of Cardiology provide guidelines for the management of ventricular tachycardia (VT), including polymorphic VT and torsades de pointes 1, 2, 3, 4

The American Heart Association recommends intravenous magnesium sulfate as the first-line treatment for polymorphic ventricular tachycardia (VT) associated with QT prolongation (torsades de pointes), with a dosing regimen that may include a 2g IV bolus over 1-5 minutes, followed by a continuous infusion of 3-20 mg/min for 7-48 hours until QT interval normalizes 5, 6
Intravenous amiodarone is the recommended initial medication for sustained ventricular tachycardia, particularly for hemodynamically stable monomorphic VT with or without severe congestive heart failure or acute myocardial infarction, as recommended by the American Heart Association 6

Temporary overdrive pacing and isoproterenol (if no contraindications) may be used for pause-dependent torsades 6
Discontinuation of all QT-prolonging medications and correction of electrolyte abnormalities (maintaining potassium in high-normal range) are also recommended 6
Electrical cardioversion/defibrillation is the first-line intervention for hemodynamically unstable VT, according to the European Heart Journal 3
Direct current cardioversion with appropriate sedation is the first-line treatment for patients with sustained polymorphic VT with hemodynamic compromise, as recommended by the European Society of Cardiology 4

Condition	Treatment
Torsades de pointes	Suspension of QT-prolonging medications, intravenous magnesium sulfate, correction of electrolyte disturbances, temporary pacing or isoproterenol in pause-dependent cases [4, 7]
PVT not associated with long QT	Defibrillation, beta-blockers IV, amiodarone IV, consideration of urgent angiography if ischemia cannot be excluded [4]

For monophasic waveform, starting with 200 J has a 95% success rate, and increasing in 100 J increments to a maximum of 400 J is recommended 8, 9
For biphasic waveform, starting with 100-150 J is recommended, and it is more effective than monophasic (99.1% vs 92.4% success) 9
For polymorphic VT/ventricular fibrillation, using unsynchronized shock (defibrillation) at 200 J initially, and increasing to 200-300 J, then 360 J if unsuccessful, is recommended 10
Maintaining at least 1-minute intervals between shocks to prevent myocardial damage is recommended 8, 9

After acute stabilization with IV amiodarone, evaluation for underlying structural heart disease, consideration of electrophysiology study and catheter ablation, and evaluation for ICD placement in high-risk patients are recommended, as stated by the American College of Cardiology 11
Transition to oral amiodarone is typically recommended, with an initial dose of 800-1600mg/day, followed by a maintenance dose of 200-400mg/day, as suggested by the American Family Physician 11
Radiofrequency catheter ablation plus ICD implantation is recommended with a Class IIa, Level C indication, as the most effective treatment for reducing VT burden and appropriate ICD shocks, as recommended by the European Society of Cardiology 3
Oral beta-blockers should be continued long-term in all patients without contraindications, with a Class IIa, Level B recommendation from the European Society of Cardiology 3
Oral amiodarone may be considered for patients with recurrent VT despite beta-blockers, as suggested by the European Heart Journal 3